NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...

Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...

Reprogramming requests requiring congressional approval currently take between four and six months. This accounts for the time from a reprogramming request being identified by the DoD to it being ...

A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The discovery demonstrates a ...